Skip to main content
search

Posters

Sign up

Featured poster

Latest posters

Popular posters

A Scalable Cloud Platform Accelerates QSP Virtual Patient Generation
A Scalable Cloud Platform Accelerates QSP Virtual Patient GenerationPoster

A Scalable Cloud Platform Accelerates QSP Virtual Patient Generation

Difference in efficacy between anti-PD-1 and anti-PD-L1 antibodies may be attributable to PD-1:PD-L2 complex inhibition, rather than differences in PD-1:PD-L1 inhibition
Difference in efficacy between anti-PD-1 and anti-PD-L1 antibodies may be attributable to PD-1:PD-L2 complex inhibition, rather than differences in PD-1:PD-L1 inhibitionPoster

Difference in efficacy between anti-PD-1 and anti-PD-L1 antibodies may be attributable to PD-1:PD-L2 complex inhibition, rather than differences in PD-1:PD-L1 inhibition

Cumulative drug binding to Cerebral Amyloid Angiopathy (CAA) predicts ARIA-E incidence for anti-Aβ antibodies in Alzheimer’s Disease
Cumulative drug binding to Cerebral Amyloid Angiopathy (CAA) predicts ARIA-E incidence for anti-Aβ antibodies in Alzheimer’s DiseasePoster

Cumulative drug binding to Cerebral Amyloid Angiopathy (CAA) predicts ARIA-E incidence for anti-Aβ antibodies in Alzheimer’s Disease

QSP model of neuroinflammation: Effect of TREM2 stimulation on microglial activation and function in the context of Alzheimer’s disease
QSP model of neuroinflammation: Effect of TREM2 stimulation on microglial activation and function in the context of Alzheimer’s diseasePoster

QSP model of neuroinflammation: Effect of TREM2 stimulation on microglial activation and function in the context of Alzheimer’s disease

Population Pharmacokinetics (PopPK) of Revumenib in Patients with Relapsed/Refractory Acute Leukemias
Population Pharmacokinetics (PopPK) of Revumenib in Patients with Relapsed/Refractory Acute LeukemiasPoster

Population Pharmacokinetics (PopPK) of Revumenib in Patients with Relapsed/Refractory Acute Leukemias

Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA
Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMAPoster

Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA

All posters

Mechanistic Modeling Guides Bispecific Antibody Design and Target Selection for Maximizing Therapeutic Window

Modeling and Simulation - QSP, Oncology/Hematology, Poster

Comparison Across Anti-PD-1 Antibodies – Insights From QSP-Based Meta-Analysis 

Modeling and Simulation - QSP, Poster

Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease

Clinical Pharmacology, Clinical Trials, Drug Development, Drug Safety, Formulation, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, PopPK Modeling and Simulation, Poster

Dose Guidance for a Novel Combination Therapy to Treat Head and Neck Squamous Cell Carcinoma (HNSCC) for Patients with HRAS/PIK3CA Variants Using a Quantitative Systems Pharmacology (QSP) Model​

Modeling and Simulation - QSP, Poster

A Scalable Cloud Platform Accelerates QSP Virtual Patient Generation

Modeling and Simulation - QSP, Poster

Difference in efficacy between anti-PD-1 and anti-PD-L1 antibodies may be attributable to PD-1:PD-L2 complex inhibition, rather than differences in PD-1:PD-L1 inhibition

Modeling and Simulation - QSP, Poster

Cumulative drug binding to Cerebral Amyloid Angiopathy (CAA) predicts ARIA-E incidence for anti-Aβ antibodies in Alzheimer’s Disease

Modeling and Simulation - QSP, Poster

QSP model of neuroinflammation: Effect of TREM2 stimulation on microglial activation and function in the context of Alzheimer’s disease

Modeling and Simulation - QSP, Poster

Population Pharmacokinetics (PopPK) of Revumenib in Patients with Relapsed/Refractory Acute Leukemias

Clinical Pharmacology, Clinical Trials, Drug Development, Drug Safety, Model Informed Drug Development, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Rare and Neglected Diseases, Poster

Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA

Immuno-oncology, Model-Based Meta-Analysis (MBMA), Modeling and Simulation, Modeling and Simulation - QSP, Therapeutic Specialties, Poster

Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi

Clinical Pharmacology, Clinical Trials, Data Standards, Data Visualization, Drug Development, Drug Safety, Formulation, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PK/PD, PopPK Modeling and Simulation, pre-update, Poster

Population pharmacokinetic modeling of TBA-7371 in healthy participants describes apparent auto-induction of clearance and predicts PK in participants with Mycobacterium tuberculosis.

Clinical Pharmacology, Clinical Trials, Data Standards, Data Visualization, Drug Development, Drug Safety, Formulation, Infectious Disease, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PK/PD, PopPK Modeling and Simulation, pre-update, Poster
Be the first to get the latest

Transforming drug development is not just our goal—it’s our obsession. If it’s yours too, then be the first to know of new insights and join us in pushing the boundaries of science.